ATE191847T1 - Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung - Google Patents

Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung

Info

Publication number
ATE191847T1
ATE191847T1 AT92121318T AT92121318T ATE191847T1 AT E191847 T1 ATE191847 T1 AT E191847T1 AT 92121318 T AT92121318 T AT 92121318T AT 92121318 T AT92121318 T AT 92121318T AT E191847 T1 ATE191847 T1 AT E191847T1
Authority
AT
Austria
Prior art keywords
aminoguamidine
production
oxide formation
nitrogen oxide
medicinal product
Prior art date
Application number
AT92121318T
Other languages
English (en)
Inventor
Joseph Robert Williamson
John Andrew Corbett
Michael Lynn Mcdaniel
Ronald Gene Tilton
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE191847T1 publication Critical patent/ATE191847T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92121318T 1991-12-16 1992-12-15 Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung ATE191847T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80791291A 1991-12-16 1991-12-16

Publications (1)

Publication Number Publication Date
ATE191847T1 true ATE191847T1 (de) 2000-05-15

Family

ID=25197413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92121318T ATE191847T1 (de) 1991-12-16 1992-12-15 Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung

Country Status (5)

Country Link
EP (1) EP0547558B1 (de)
JP (1) JP3251673B2 (de)
AT (1) ATE191847T1 (de)
CA (1) CA2085399A1 (de)
DE (1) DE69230928T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358969A (en) * 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
EP0670720A1 (de) * 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzymhemmer
PL180081B1 (pl) * 1993-08-12 2000-12-29 Astra Ab Nowe pochodne amidyny i sposób ich wytwarzania PL PL PL PL PL PL PL
CA2176747A1 (en) * 1993-11-17 1995-05-26 J. Brice Weinberg Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
CA2188680A1 (en) * 1994-05-07 1996-01-25 James Edwin Macdonald Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
US5929063A (en) * 1995-03-24 1999-07-27 Children's Hospital Medical Center Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US5674907A (en) * 1995-03-24 1997-10-07 Children's Hospital Medical Center Mercapto derivatives as inhibitors of nitric oxide synthase
US5780513A (en) * 1996-08-22 1998-07-14 Washington University Method of inhibiting the release of bioactive IL-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
EP0339496A3 (de) * 1988-04-26 1991-05-08 Ono Pharmaceutical Co., Ltd. Aminoguanidine Derivate

Also Published As

Publication number Publication date
JPH05255079A (ja) 1993-10-05
EP0547558A1 (de) 1993-06-23
CA2085399A1 (en) 1993-06-17
DE69230928D1 (de) 2000-05-25
DE69230928T2 (de) 2001-01-11
EP0547558B1 (de) 2000-04-19
JP3251673B2 (ja) 2002-01-28

Similar Documents

Publication Publication Date Title
DK0480077T3 (da) Fremgangsmåde til fremstilling af carnosinsyre
ATE76744T1 (de) Kosmetische zusammensetzung.
ATE330606T1 (de) Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden
DE69435194D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
ATE214608T1 (de) Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
CA2090574A1 (en) Method of inhibiting nitric oxide formation
ES2081120T3 (es) Procedimiento para la preparacion de derivados de la bacatina iii y la desacetil-10 bacatina iii.
ATE191847T1 (de) Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
DE69125035D1 (de) Verfahren zur herstellung von interferon-alpha-2 kristallen
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
DK0380331T3 (da) Anvendelse af di-tert.butylhydroxyphenylthioderivater til fremstilling af et lægemiddel til behandling eller forebyggelse af arteriosklerose eller atherosklerose
DE69122364D1 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
ATE174508T1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69427711D1 (de) Verfahren zur hemmung der stickstoffoxidbildung
LU79376A1 (de) 1,2,3-thiadiazol-3-in-5-yliden-harnstoffe,verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit wachstumsregulatorischer wirkung
ATE129407T1 (de) Verwendung von biphosphonaten zur herstellung eines arzneimittels zur blockierung neoplastischer zelltransformationen die durch ras-oncogene verursacht werden.
CA2078700A1 (en) Imidazolylmethyl-pyridines
DE59207888D1 (de) Verfahren zur Herstellung von entspiegelten Oberflächen
ATE146185T1 (de) 11beta-substituierte 14,17-ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
LU81578A1 (de) 1,2,3-triazolcarbonsaeureamide,verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel
DE59105327D1 (de) Verfahren zur Herstellung eines Feuchthaltemittels.
DE69322516D1 (de) Durch phosphorsäureester modifiziertes polysiloxan und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee